Abstract
Malignant peritoneal mesothelioma (MPM) is an incurable disease. It represents approximately 15% of all mesotheliomas and has a male predominance. It has a known relationship to asbestos, but most patients present with no known history of exposure. Simian virus 40 (SV40) exposure is potentially another risk factor, although the relationship is not entirely supported. Patients usually present with vague symptoms. Diagnosis is usually made on the basis of a CT scan and percutaneous or open biopsy. The disease remains confined to the abdominal cavity until very late in the disease course. Ascites is a frequent sign; morbidity and mortality are usually a consequence of disease progression within the abdominal cavity. Systemic chemotherapy and radiation have not yet been shown to have much influence over the natural history of the disease. In selected patients, surgical cytoreduction with intraoperative hyperfhermic peritoneal chemotherapy is associated with long-term survival. A summary of clinical experience with surgical cytoreduction and intraoperative intraperitoneal chemotherapy for MPM is presented.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 2003;12:605–621, xi.
Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560–4567.
Cancer Surveillance. 2005. Ref Type: Internet Communication
Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in aregistry of 180 patients, the Dana Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 1988;6:147–153.
SEER. Cancer Statistics Review—Mesothelioma fast stats. 2005.
Weill H, Hughes JM, Churg AM. Changing trends in US mesothelioma incidence. Occup Environ Med 2004;61:438–441.
Zellos L, Christiani DC. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin 2004;14:469–477, viii.
Landrigan PJ. Asbestos—still a carcinogen. N Engl J Med 1998;338:1618–1619.
Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 2000;44:565–601.
Camus M, Siemiatycki J, Meek B. Nonoccupational exposure to chrysotile asbestos and the risk of lung cancer. N Engl J Med 1998;338:1565–1571.
McDonald AD, McDonald JC. Malignant mesothelioma in North America. Cancer 1980;46: 1650–1656.
Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002;29:2–17.
Carbone M, Pass HI, Miele L, Bocchetta M. New developments about the association of SV40 with human mesothelioma. Oncogene 2003;22:5173–5180.
Foddis R, De Rienzo A, Broccoli D, et al. SV40 infection induces telomerase activity in human mesothelial cells. Oncogene 2002;21:1434–1442.
Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001;357:444–445.
Austin MB, Fechner RE, Roggli VL. Pleural malignant mesothelioma following Wilms’ tumor. Am J Clin Pathol 1986;86:227–230.
Sanders CL, Jackson TA. Induction of mesotheliomas and sarcomas from “hot spots” of 239 PuO 2 activity. Health Phys 1972;22:755–759.
Powell JE, Stevens MC, Stiller CA. Clustering of childhood peritoneal mesothelioma in the Midlands, UK. Lancet 1995;345:66–67.
Kelsey A. Mesothelioma in childhood. Pediatr Hematol Oncol 1994;11:461–462.
Niggli FK, Gray TJ, Raafat F, Stevens MC. Spectrum of peritoneal mesothelioma in childhood: clinical and histopathologic features, including DNA cytometry. Pediatr Hematol Oncol 1994; 11:399–408.
Corson JM. Pathology of mesothelioma. Thorac Surg Clin 2004; 14:447–460.
Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000;24:1183–1200.
Suzuki Y. Diagnostic criteria for human diffuse malignant mesothelioma. Acta Pathol Jpn 1992;42:767–786.
Kannerstein M, Churg J. Peritoneal mesothelioma. Hum Pathol 1977;8:83–94.
Dhaene K, Hubner R, Kumar-Singh S, Weyn B, Van Marck E. Telomerase activity in human pleural mesothelioma. Thorax 1998;53:915–918.
Dhaene K, Wauters J, Weyn B, Timmermans JP, Van Marck E. Expression profile of telomerase subunits in human pleural mesothelioma. J Pathol 2000;190:80–85.
Kumaki F, Kawai T, Churg A, et al. Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol 2002;26:365–370.
Rosai J. Rosai and Ackerman’sSurgical Pathology. 9th ed. Edinburgh-London-New York: Mosby-Elsevier; 2004.
Ordonez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998;11:929–933.
Trupiano JK, Geisinger KR, Willingham MC, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004;17:476–481.
Dazzi H, Hasleton PS, Thatcher N, Wilkes S, Swindell R, Chatterjee AK. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990;61:924–926.
Averbach AM, Sugarbaker PH. Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res 1996;81:193–211.
Kebapci M, Vardareli E, Adapinar B, Acikalin M. CT findings and serum CA 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature. Eur Radiol 2003;13: 2620–2626.
Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol 1981;8:313–320.
van Gelder T, Hoogsteden HC, Versnel MA, de Beer P, Vandenbroucke JP, Planteydt HT. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 1989;43:222–227.
Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980;68:356–362.
Hedman M, Arnberg H, Wernlund J, Riska H, Brodin O. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res 2003;23:531–536.
Dahl IM, Solheim OP, Erikstein B, Muller E. A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease. Cancer 1989;64:68–73.
Frebourg T, Lerebours G, Delpech B, et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer 1987;59:2104–2107.
Ros PR, Yuschok TJ, Buck JL, Shekitka KM, Kaude JV. Peritoneal mesothelioma. Radiologie appearances correlated with histology. Acta Radiol 1991;32:355–358.
Antman K, Pomfret F, Aisner J, et al. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1983;1:386.
Plaus WJ. Peritoneal mesothelioma. Arch Surg 1988;123:763–766.
Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003; 89:269–273.
Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005;103: 839–849.
Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous cacinomas. Am J Surg Pathol 1998;22:1203–1214.
Ordonez NG. The immunohistochemical diagnosis of epithelial mesothelioma. Hum Pathol 1999;30:313–323.
Roberts F, Harper CM, Downie I, Burnett RA. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001;116:253–262.
Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 2002;40:237–244.
Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary andnonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598–606.
Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005;32:151–155.
Ruan Q, Hu Y. Immunophenotypings of malignant epithelial mesothelioma and their roles in the differential diagnosis. J Huazhong Univ Sci Techn Med Sci 2004;24:112–115.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Mangiameli, D.P., Libutti, S.K., Pingpank, J.F., Alexander, H.R. (2007). Malignant Peritoneal Mesothelioma. In: Schlag, P.M., Stein, U., Eggermont, A.M.M. (eds) Regional Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-225-0_16
Download citation
DOI: https://doi.org/10.1007/978-1-59745-225-0_16
Publisher Name: Humana Press
Print ISBN: 978-1-58829-672-6
Online ISBN: 978-1-59745-225-0
eBook Packages: MedicineMedicine (R0)